You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科兴:截至1月10日已供应逾700万剂灭活疫苗至各省
阿思达克 01-13 15:49
科兴生物(SVA.US)董事长尹卫东表示,科兴生物的新冠灭活疫苗克尔来福在去年4月份进入了I期和II期临床研究。截止到1月10日已经超过了700万剂灭活疫苗供应到各省,特别是北京、广东等省,已经大规模接种,已经看到了良好的安全性效果,有效性公司正在研究和追踪当中。

他续指,科兴中维的生产线目前一期已经完成了年产5亿剂的疫苗建设,并且投入了正式的生产。经过中国国家药监局的GMP验收,同时完成了巴西、土耳其、新加坡和智利的GMP检查,能够充分保障现在疫苗的需求,相信有10亿剂的产能能够保障供应。

另外,公司陆续收到多个国家向科兴中维发出的新冠灭活疫苗的订单,包括印尼、土耳其、马来西亚、新加坡、菲律宾等国,已经分别与公司签署了疫苗供应的协议。(el/u) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account